Senores Pharma expects to cross ₹3,000 crore revenue target ahead of schedule

Swapnil Shah, Managing Director of Senores Pharmaceuticals, expects growth to be driven by new US subsidiaries, 12 ANDA launches, expanding CDMO operations, and a pipeline of over 116 products, while maintaining 25-30% annual revenue growth and improving profitability.